Credit Suisse analyst Vamil Divan maintained a Buy rating on Allergan (AGN) yesterday and set a price target of $200. The company’s shares closed yesterday at $150.86, close to its 52-week low of $142.81.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -3.2% and a 42.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
Currently, the analyst consensus on Allergan is a Strong Buy with an average price target of $215.80, implying a 43.0% upside from current levels. In a report issued on November 30, RBC Capital also maintained a Buy rating on the stock with a $220 price target.
.
See today’s analyst top recommended stocks >>
Based on Allergan’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $37.9 million. In comparison, last year the company had a GAAP net loss of $3.96 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.
